Roelien Postema

Roelien advises clients on their access and evidence generation strategy from early assets through launch and beyond. She leads and contributes to a range of projects with a strategic angle in access, health economics and HTA policy.

Roelien brings over 14 years of experience in the field of health economics, market access, and real-world evidence. Through her roles at Lilly, BMS, and Galapagos, she has gained extensive experience in value and evidence generation strategy across a wide range of therapeutic areas, supporting countries in preparation of HTA dossiers, and development of evidence such as health economic models, indirect treatment comparisons, and real-world evidence studies. She also gained experience in providing health economics and market access insight into early drug development and for mergers and acquisitions.

Roelien has a PharmD from the University of Groningen and a Postgraduate Diploma in Epidemiology from the London School of Hygiene and Tropical Medicine.